-
The fda has approved a higher dose of the rivastigmine transdermal system (13.3 mg/24 hours) for the treatment of Alzheimer's disease (AD). Lower-dose patches were previously approved for mild-to-moderate disease. Rivastigamine is a reversible acetylcholinesterase inhibitor. The transdermal system is marketed by Novartis as Exelon.
-
The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial randomized 1376 patients with AF and CHF to rhythm- or rate-control treatment strategies.
-
This study examines the influence of renal dysfunction on stroke risks in two atrial fibrillation (AF) study groups. The ROCKET AF trial was a trial comparing fixed-dose rivaroxaban, a direct factor Xa inhibitor, with adjusted-dose warfarin for prevention of thromboembolic events.
-
Aspirin use and AMD risk; using NSAIDs and antihypertensive agents; and FDA actions.
-
The accurate and timely recognition of acute coronary syndromes (ACS) may facilitate the deployment of evidence-based therapies that could impact outcomes.
-
Beta-blockers are widely considered first-line therapy for heart rate control in patients with permanent atrial fibrillation (AF), but few comparative effectiveness data with other drugs are available.
-
During coronary artery bypass graft (CABG) surgery, the aim is to achieve complete revascularization of all the coronary arteries.
-
The appearance of right bundle branch block (RBBB) and incomplete RBBB (IRBBB) in otherwise healthy individuals is believed to be benign, but several cardiac and pulmonary diseases are known to be associated with RBBB and IRBBB.
-
-
Volume infusion during right heart catheterization has been recommended to distinguish patients with pulmonary hypertension (PH) from those with heart failure with preserved ejection fraction (HFpEF).
